

WEST VIRGINIA LEGISLATURE

2026 REGULAR SESSION

Introduced

House Bill 4640

By Delegates Worrell and Hite

[Introduced January 21, 2026; referred to the
Committee on Health and Human Resources]

1 A BILL to amend and reenact §60A-2-204 of the Code of West Virginia, 1931, as amended,
2 relating to schedule I drugs; and adding a provision relating to the scheduling of an organic
3 psilocybin substance or crystalline polymorph psilocybin approved by the Food and Drug
4 Administration and the Drug Enforcement Administration.

Be it enacted by the Legislature of West Virginia:

ARTICLE 2. STANDARDS AND SCHEDULES.

§60A-2-204.	Schedule	I.
1 (a) Schedule I shall consist of the drugs and other substances, by whatever official name, 2 common or usual name, chemical name, or brand name designated, listed in this section including 3 their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the 4 existence of such isomers, esters, ethers, and salts is possible within the specific chemical 5 designation.		
6 (b) Opiates.		
7 Acetyl-alpha-methylfentanyl(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]- 8 phenylacetamide);		
9 Acetylmethadol;		
10 Allylprodine;		
11 Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha- 12 acetylmethadol, levomethadyl acetate, or LAAM);		
13 Alphameprodine;		
14 Alphamethadol;		
15 Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 16 1-(1-methyl-2-phenylethyl)-4-((propanilido) piperidine);		
17 Alpha-methylthiofentanyl 18 phenylpropanamide);	(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-	
19 Benzethidine;		

20 Betacetylmethadol;
21 Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-
22 phenylpropanamide);
23 Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
24 piperidinyl]-N-phenylpropanamide);
25 Betameprodine;
26 Betamethadol;
27 Betaprodine;
28 Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-
29 2-one);
30 Clonitazene;
31 Dextromoramide;
32 Diamprodime;
33 Diethylthiambutene;
34 Difenoxin;
35 Dimenoxadol;
36 Dimepheptanol;
37 Dimethylthiambutene;
38 Dioxaphetyl butyrate;
39 Dipipanone;
40 Ethylmethylthiambutene;
41 Etonitazene;
42 Etoxeridine;
43 Fentanyl analog or derivative, as that term is defined in article one of this chapter:
44 Provided, That fentanyl and carfentanil remains a Schedule II substance, as set forth in W. Va.
45 Code §60A-2-206;

46 Furethidine;
47 Hydroxypethidine;
48 Ketobemidone;
49 Levomoramide;
50 Levophenacylmorphan;
51 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
52 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-phenylpropanamide);
53 Morpheridine;
54 N-Methylnorfentanyl (N-(1-Methyl-4-piperidinyl)-N-phenyl-propanamide,
55 monohydrochloride);
56
57 MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
58 Noracymethadol;
59 Norlevorphanol;
60 Normethadone;
61 Norpipanone;
62 Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide);
63 PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxy piperidine);
64 Phenadoxone;
65 Phenampromide;
66 Phenomorphan;
67 Phenoperidine;
68 Piritramide;
69 Proheptazine;
70 Properidine;
71 Propiram;

72 Racemoramide;
73 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
74 Tilidine;
75 Trimeperidine.
76 (c) Opium derivatives,
77 Acetorphine;
78 Acetyldihydrocodeine;
79 Benzylmorphine;
80 Codeine methylbromide;
81 Codeine-N-Oxide;
82 Cyprenorphine;
83 Desomorphine;
84 Dihydromorphine;
85 Drotebanol;
86 Etorphine (except HCl Salt);
87 Heroin;
88 Hydromorphenol;
89 Methyldesorphine;
90 Methyldihydromorphine;
91 Morphine methylbromide;
92 Morphine methylsulfonate;
93 Morphine-N-Oxide;
94 Myrophine;
95 Nicocodeine;
96 Nicomorphine;
97 Normorphine;

124 3,4-methylenedioxymethamphetamine (MDMA);
125 3,4-methylenedioxy-N-ethylamphetamine (also known as (ethyl-alpha-methyl-3,4
126 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
127 N-hydroxy-3,4-methylenedioxymphetamine (also known as (hydroxy-alpha-methyl-3,4
128 (methylenedioxy) phenethylamine, and (hydroxy MDA);
129 3,4,5-trimethoxy amphetamine;
130 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
131 Alpha-methyltryptamine (other name: AMT);
132 Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-
133 hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
134 dimethyltryptamine; mappine;
135 Diethyltryptamine; sometrade and other names: N, N-Diethyltryptamine; DET;
136 Dimethyltryptamine; some trade or other names: DMT;
137 5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);
138 Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-
139 methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
140 Lysergic acid diethylamide;
141 Marihuana; Marijuana (Cannabis, sp.);
142 Mescaline;
143 Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6,
144 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
145 Peyote; meaning all parts of the plant presently classified botanically as Lophophora
146 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
147 plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of
148 such plant, its seeds or extracts;
149 N-ethyl-3-piperidyl benzilate;

150 N-methyl-3-piperidyl benzilate;

151 Psilocybin;

152 Psilocyn;

153 Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant, or

154 in the resinous extractives of Cannabis, sp. and/or synthetic substances, immediate derivatives

155 and their isomers with similar chemical structure and pharmacological activity including, but not

156 limited to the following:

157 delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;

158 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;

159 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;

160 delta-8 Cis or trans tetrahydrocannabinol and its optical isomers; and

161 delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;

162 (Since nomenclature of these substances is not internationally standardized, compounds

163 of these structures, regardless of numerical designation of atomic positions covered.)

164 Delta-8-tetrahydrocannabinol-O (delta-8-THC-O), Delta-9-tetrahydrocannabinol (delta-9-

165 THC-O) and Synthetic and non-naturally occurring cannabinoids.

166 The provisions of this section related to tetrahydrocannabinols are inapplicable to

167 products or substances lawfully manufactured, distributed, or possessed under the provisions of §

168 19-12E-1 *et seq.* and Chapter 16H of this code.

169 Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-

170 phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,

171 cyclohexamine, PCE;

172 Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-

173 pyrrolidine, PCPy, PHP;

174 Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)-

175 cyclohexyl]-piperidine, 2-thienyl analog of phencyclidine; TPCP, TCP;

176 1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy;
177 4-methylmethcathinone (Mephedrone);
178 3,4-methylenedioxypyrovalerone (MDPV);
179 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
180 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
181 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
182 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
183 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
184 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
185 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
186 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
187 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
188 3,4-Methylenedioxy-N-methylcathinone (Methylone);
189 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7, its optical isomers, salts and
190 salts of isomers;
191 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
192 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT);
193 Alpha-methyltryptamine (other name: AMT);
194 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
195 Synthetic Cannabinoids as follows:
196 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol { also known as CP
197 47,497 and homologues} ;
198 rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol { also known as CP
199 47,497-C8 homolog} ;
200 [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-
201 tetrahydrobenzo[c]chromen-1-ol)] { also known as HU-210} ;

202 (dexanabinol);
203 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
204 tetrahydrobenzol[c]chromen-1-ol) { also known as HU-211} ;
205 1-Pentyl-3-(1-naphthoyl)indole { also known as JWH-018} ;
206 1-Butyl-3-(1-naphthoyl)indole { also known as JWH-073} ;
207 (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone { also known as JWH-015} ;
208 (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone { also known as JWH-019} ;
209 [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone { also known as
210 JWH-200} ;
211 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone { also known as JWH-250} ;
212 2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol {
213 also known as CP 55,940} ;
214 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH-
215 122};
216 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH-398};
217 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone { also known as RCS-4} ;
218 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone { also known as
219 RCS-8} ;
220 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
221 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
222 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
223 Synthetic cannabinoids:
224 CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
225 YL)phenol);
226 HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
227 10A-tetrahydrobenzo[C] chromen-1-OL)];

228 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-
229 YL)-6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
230 JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
231 JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
232 JWH-073, 1-butyl-3-(1-naphthoyl)indole;
233 JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
234 JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
235 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-
236 ADB);
237 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
238 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
239 AMB);
240 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
241 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
242 (ADB-FUBINACA);
243 Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
244 (MDMB-CHMICA);
245 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-
246 FUBINACA);
247 Tetrahydrocannabinols:
248 DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.
249 DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
250 DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
251 Synthetic Phenethylamines
252 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
253 NBOMe);

254 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C-
255 NBOMe);
256 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B-
257 NBOMe);
258 Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters
259 and ethers):
260 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
261 furanyl fentanyl;
262 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
263 47700);
264 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
265 phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
266 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also known
267 as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, (beta-
268 hydroxythiofentanyl);
269 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);
270 N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
271 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);
272 2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
273 (also known as U-48800);
274 Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as
275 U-49900);
276 Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also
277 known as U-51754);
278 2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
279 (butoritazene);

280 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
281 N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
282 (flunitazene);
283 N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
284 (metodesnitazene);
285 N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
286 (metonitaze);
287 2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-pyrrolidino
288 etonitazene, etonitazepyne);
289 N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
290 (protonitazene);
291 N-pyrrolidino etonitazene;
292 Etodesnitazene;
293 Isotonitazene;
294 Protonitazene;
295 Metonitazene;
296 Butonitazene;
297 Metodesnitazene;
298 Flunitazene;
299 Opioid Receptor Agonist
300 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one)
301 AH-7921 (3,4-dichloro-N-(1dimethylamino)cyclohexylmethyl]benzamide).
302 Naphthoylindoles or any compound containing a 3-(1-Naphthoyl) indole structure with
303 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
304 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
305 include the following:

306 JWH 015;

307 JWH 018;

308 JWH 019;

309 JWH 073;

310 JWH 081;

311 JWH 122;

312 JWH 200;

313 JWH 210;

314 JWH 398;

315 AM 2201; and

316 WIN 55,212.

317 Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane structure with a substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include, but not be limited to, JWH 175 and JWH 184.

321 Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include, but not be limited to, JWH 147 and JWH 307.

325 Naphthylmethylindenes or any compound containing a Naphthylideneindene structure with substitution at the 3- Position of the indene ring whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include, but not be limited to, JWH 176.

329 Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include

332 the following:

333 RCS-8, SR-18 OR BTM-8;

334 JWH 250;

335 JWH 203;

336 JWH 251; and

337 JWH 302.

338 Cyclohexylphenols or any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the cyclohexyl ring to any extent. This shall include the following:

341 CP 47,497 and its homologues and analogs;

342 Cannabicyclohexanol; and

343 CP 55,940.

344 Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include the following:

348 AM 694;

349 Pravadoline WIN 48,098;

350 RCS 4; and

351 AM 679.

352 [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-naphthalenymethanone. This shall include WIN 55,212-2.

354 Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051, and JWH 133.

357 Adamantoylindoles or any compound containing a 3-(1-Adamantoyl) indole structure with

358 substitution at the nitrogen atom of the indole ring whether or not further substituted in the
359 adamantoyl ring system to any extent. This shall include AM1248.

360 Tetramethylcyclopropylindoles or any compound containing A 3-
361 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring
362 whether or not further substituted in the indole ring to any extent and whether or not substituted in
363 the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.

364 N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.

365 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
366 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
367 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
368 medical research. Since nomenclature of these substances is not internationally standardized,
369 any immediate precursor or immediate derivative of these substances shall be covered.

370 Tryptamines:

371 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);

372 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

373 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);

374 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

375 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);

376 5-methoxy- α -methyltryptamine (5-MeO-AMT);

377 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);

378 4-hydroxy Diethyltryptamine (4-HO-DET);

379 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);

380 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);

381 4-hydroxy Diethyltryptamine (4-HO-DET);

382 FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);

383 FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);

384 5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
385 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
386 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
387 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
388 Methyl-Ethylaminopentiophenone;
389 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
390 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
391 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
392 carboxamide);
393 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
394 methylbutanoat);
395 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
396 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
397 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
398 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
399 Methyl-Ethylaminopentiophenone;
400 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
401 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
402 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
403 carboxamide);
404 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
405 methylbutanoat);
406 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
407 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-
408 a][1,4]benzodiazepine);
409 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-

410 benzodiazepin-2-one);

411 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
412 a][1,4]diazepine);

413 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
414 a][1,4]benzodiazepine);

415 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

416 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
417 a][1,4]benzodiazepine);

418 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
419 a][1,4]diazepine);

420 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
421 one) ;

422 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine); and

423 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
424 a][1,4]benzodiazepine).

425 (e) Depressants.

426 4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-
427 carboxamide);

428 Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);

429 2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone,
430 monohydrochloride);

431 4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);

432 Mecloqualone;

433 Methaqualone;

434 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

435 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-

436 a][1,4]benzodiazepine);

437 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-
438 benzodiazepin-2-one);

439 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
440 a][1,4]diazepine);

441 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
442 a][1,4]benzodiazepine);

443 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

444 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
445 a][1,4]benzodiazepine);

446 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
447 a][1,4]diazepine);

448 gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate; 4-
449 hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

450 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
451 one);

452 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

453 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
454 a][1,4]benzodiazepine);

455 Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
456 one); and

457 Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-
458 a][1,4]diazepine);

459 (f) Stimulants.

460 Aminorex; some other names: aminoxyphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-
461 dihydro-5-phenyl-2-oxazolamine;

462 4,4'-Dimethylaminorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-
463 methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
464 Cathinone; some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-
465 aminopropiophenone, 2-aminopropiophenone and norephedrone;
466 Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
467 Fenethylline;
468 Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
469 Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
470 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
471 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
472 methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or
473 mephedrone;3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone;
474 methylcathinone; AL-464; AL-422; AL-463 and UR1432;
475 (+-) cis-4-methylaminorex; ((+)-cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
476 N-ethylamphetamine;
477 N,N-dimethylamphetamine; also known as N,N-alpha-trimethyl-benzeneethanamine;
478 N,N-alpha-trimethylphenethylamine;
479 Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
480 salts of isomers;
481 Substituted amphetamines:
482 2-Fluoroamphetamine;
483 3-Fluoroamphetamine;
484 4-Fluoroamphetamine;
485 2-chloroamphetamine;
486 3-chloroamphetamine;
487 4-chloroamphetamine;

488 2-Fluoromethamphetamine;
489 3-Fluoromethamphetamine;
490 4-Fluoromethamphetamine;
491 4-chloromethamphetamine;
492 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
493 Alpha-PHP (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
494 MPHP (1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
495 PV8 (1-Phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
496 4-Chloro-Alpha-PVP (1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
497 N-Ethylhexedrone (2-(Ethylamino)-1-phenylhexan-1-one);
498 Methoxetamine (2-(Ethylamino)-2-(3-methoxyphenyl)-cyclohexanone); and
499 3-Fluorophenmetrazine (2-(3-Fluorophenyl)-3-methylmorpholine);
500 (g) Temporary listing of substances subject to emergency scheduling. Any material,
501 compound, mixture, or preparation which contains any quantity of the following substances:
502 N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts,
503 and salts of isomers;
504 N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
505 isomers, salts, and salts of isomers.
506 N-benzylpiperazine, also known as BZP;
507 Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
508 4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-
509 butyramide);
510 Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
511 Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
512 acetamide);
513 3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-

514 phenylbutyramide);
515 4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
516 yl)butyramide);
517 Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
518 Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
519 carboxamide); and
520 Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).

521 (h) The following controlled substances are included in Schedule I:
522 Synthetic Cathinones or any compound, except bupropion or compounds listed under a
523 different schedule, or compounds used within legitimate and approved medical research,
524 structurally derived from 2-Aminopropan-1-one by substitution at the 1-position with Monocyclic or
525 fused polycyclic ring systems, whether or not the compound is further modified in any of the
526 following ways:

527 By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,
528 hydroxyl, or halide Substituents whether or not further substituted in the ring system by one or
529 more other univalent substituents;

530 By substitution at the 3-position with an acyclic alkyl substituent;

531 By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
532 groups;

533 By inclusion of the 2-amino nitrogen atom in a cyclic structure; or

534 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
535 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
536 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
537 medical research.

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section including isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the presence of such isomers, esters, ethers, and salts is possible within the specific chemical structure.

(b) Opiates.

Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]—acetamide);

Acetylmethadol;

Allylprodine;

Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-methadol, levomethadyl acetate, or LAAM);

Alphameprodine;

Alphamethadol;

Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; ethyl-2-phenylethyl)-4-((propanilido) piperidine);

Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidinyl]—propanamide);

Benzethidine;

Betacetylmethadol;

Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-propanamide);

Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
inyl]-N-phenylpropanamide);

Betameprodine;

Betamethadol;

53 Noracymethadol;
54 Norlevorphanol;
55 Normethadone;
56 Norpipanone;
57 Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl] propanamide);
58 PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
59 Phenadoxone;
60 Phenampromide;
61 Phenomorphan;
62 Phenoperidine;
63 Piritramide;
64 Proheptazine;
65 Properidine;
66 Propiram;
67 Racemoramide;
68 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
69 Tilidine;
70 Trimeperidine.
71 (c) Opium derivatives,
72 Acetorphine;
73 Acetyldihydrocodeine;
74 Benzylmorphine;
75 Codeine methylbromide;
76 Codeine-N-Oxide;
77 Cyprenorphine;
78 Desomorphine;

79 Dihydromorphine;
80 Drotebanol;
81 Etorphine (except HCl Salt);
82 Heroin;
83 Hydromorphenol;
84 Methyldesorphine;
85 Methyldihydromorphine;
86 Morphine methylbromide;
87 Morphine methylsulfonate;
88 Morphine-N-Oxide;
89 Myrophine;
90 Nicocodeine;
91 Nicomorphine;
92 Normorphine;
93 Pholcodine;
94 Thebacon.
95 (d) Hallucinogenic substances.
96 Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethy-1H-
97 indole-3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;
98 4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5-
99 dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;
100 4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-
101 dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;
102 N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has the
103 acronym 25B-NBOMe;
104 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe);

105 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
106 2,5-dimethoxyamphetamine; some trade or other names: 2,5-dimethoxy-alpha-
107 methylphenethylamine; 2,5-DMA;
108 2,5-dimethoxy-4-ethylamphetamine; some trade or other names: DOET;
109 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
110 4-methoxyamphetamine; some trade or other names: 4-methoxy-alpha-
111 methylphenethylamine; paramethoxyamphetamine; PMA;
112 3-Hydroxy-phenylcyclidine (other name hydroxy PCP);
113 5-methoxy-3, 4-methylenedioxy-amphetamine;
114 4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
115 dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
116 3,4-methylenedioxy amphetamine;
117 3,4-methylenedioxymethamphetamine (MDMA);
118 3,4-methylenedioxy-N-ethylamphetamine (also known as (ethyl-alpha-methyl-3,4
119 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
120 N-hydroxy-3,4-methylenedioxyamphetamine (also known as (hydroxy-alpha-methyl-3,4
121 (methylenedioxy) phenethylamine, and (hydroxy MDA);
122 3,4,5-trimethoxy amphetamine;
123 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
124 Alpha-methyltryptamine (other name: AMT);
125 Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-
126 hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
127 dimethyltryptamine; mappine;
128 Diethyltryptamine; some trade and other names: N, N-Diethyltryptamine; DET;
129 Dimethyltryptamine; some trade or other names: DMT;
130 5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);

131 Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-
132 methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
133 Lysergic acid diethylamide;
134 Marijuana; Marijuana (Cannabis, sp.);
135 Mescaline;
136 Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6,
137 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
138 Peyote; meaning all parts of the plant presently classified botanically as Lophophora
139 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
140 plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of
141 such plant, its seeds or extracts;
142 N-ethyl-3-piperidyl benzilate;
143 N-methyl-3-piperidyl benzilate;
144 Psilocybin;
145 Psilocyn;
146 Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant, or
147 in the resinous extractives of Cannabis, sp. and/or synthetic substances, immediate derivatives
148 and their isomers with similar chemical structure and pharmacological activity including, but not
149 limited to the following:
150 delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
151 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
152 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
153 delta-8 Cis or trans tetrahydrocannabinol and its optical isomers; and
154 delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;
155 (Since nomenclature of these substances is not internationally standardized, compounds
156 of these structures, regardless of numerical designation of atomic positions covered.)

157 Delta-8-tetrahydrocannabinol-O (delta-8-THC-O), Delta-9-tetrahydrocannabinol (delta-9-
158 THC-O) and Synthetic and non-naturally occurring cannabinoids.

159 The provisions of this section related to tetrahydrocannabinols are inapplicable to products
160 or substances lawfully manufactured, distributed, or possessed under the provisions of §19-12E-
161 1 *et seq.* and Chapter 16H of this code.

162 Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-
163 phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
164 cyclohexamine, PCE;

165 Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-
166 pyrrolidine, PCPy, PHP;

167 Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)-
168 cyclohexyl]-piperidine, 2-thienyl analog of phencyclidine; TPCP, TCP;

169 1[1-(2-thienyl)cyclohexyl]pyrrolidine; some other names: TCPy;

170 4-methylmethcathinone (Mephedrone);

171 3,4-methylenedioxypyrovalerone (MDPV);

172 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

173 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

174 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

175 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

176 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

177 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

178 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

179 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

180 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

181 3,4-Methylenedioxy-N-methylcathinone (Methylone);

182 2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, its optical isomers, salts and

183 salts of isomers;

184 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
185 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT);

186 Alpha-methyltryptamine (other name: AMT);

187 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);

188 Synthetic Cannabinoids as follows:

189 2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol {also known as CP
190 47,497 and homologues};

191 rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known as CP
192 47,497-C8 homolog};

193 [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-
194 tetrahydrobenzo[c]chromen-1-ol)] {also known as HU-210};

195 (dexanabinol);

196 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
197 tetrahydrobenzol[c]chromen-1-ol) {also known as HU-211};

198 1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};

199 1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};

200 (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-015};

201 (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};

202 [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as
203 JWH-200};

204 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};

205 2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxypropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol
206 {also known as CP 55,940};

207 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-122};

208 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-398};

209 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
210 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known as
211 RCS-8};
212 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
213 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
214 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
215 Synthetic cannabinoids:
216 CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
217 YL)phenol);
218 HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
219 10A-tetrahydrobenzo[C] chromen-1-OL];
220 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-
221 YL)-6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
222 JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
223 JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
224 JWH-073, 1-butyl-3-(1-naphthoyl)indole;
225 JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
226 JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
227 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-
228 ADB);
229 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
230 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
231 AMB);
232 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
233 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
234 (ADB-FUBINACA);

235 Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
236 (MDMB-CHMICA);
237 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-
238 FUBINACA);
239 Tetrahydrocannabinols:
240 DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.
241 DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
242 DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
243 Synthetic Phenethylamines
244 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
245 NBOMe);
246 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C-
247 NBOMe);
248 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B-
249 NBOMe);
250 Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters
251 and ethers):
252 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
253 furanyl fentanyl;
254 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
255 47700);
256 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
257 phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
258 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, also known
259 as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, (beta-
260 hydroxythiofentanyl);

261 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);
262 N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
263 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);
264 2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
265 (also known as U-48800);
266 Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as
267 U-49900);
268 Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also
269 known as U-51754);
270 2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
271 (butonitazene);
272 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
273 (etodesnitazene);
274 N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
275 (flunitazene);
276 N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
277 (metodesnitazene);
278 N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
279 (metonitazole);
280 2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-
281 pyrrolidino etoitazene, etonitazepyne);
282 N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
283 (protonitazene);
284 N-pyrrolidino etonitazene;
285 Etodesnitazene;
286 Isotonitazene;

287 Protonitazene;
288 Metonitazene;
289 Butonitazene;
290 Metodesnitazene;
291 Flunitazene;
292 Opioid Receptor Agonist
293 AH-7921 (3,4-dichloro-N- (1dimethylamino)cyclohexylmethyl]benzamide).
294 Naphthoylindoles or any compound containing a 3-(1- Naphthoyl) indole structure with
295 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
296 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
297 include the following:
298 JWH 015;
299 JWH 018;
300 JWH 019;
301 JWH 073;
302 JWH 081;
303 JWH 122;
304 JWH 200;
305 JWH 210;
306 JWH 398;
307 AM 2201; and
308 WIN 55,212.
309 Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane
310 structure with a substitution at the nitrogen atom of the indole ring whether or not further
311 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to
312 any extent. This shall include, but not be limited to, JWH 175 and JWH 184.

313 Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with
314 substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole
315 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
316 include, but not be limited to, JWH 147 and JWH 307.

317 Naphthylmethylindenes or any compound containing a Naphthylideneindene structure
318 with substitution at the 3- Position of the indene ring whether or not further substituted in the
319 indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This
320 shall include, but not be limited to, JWH 176.

321 Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with
322 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
323 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
324 the following:

325 RCS-8, SR-18 OR BTM-8;

326 JWH 250;

327 JWH 203;

328 JWH 251; and

329 JWH 302.

330 Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol
331 structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the
332 cyclohexyl ring to any extent. This shall include the following:

333 CP 47,497 and its homologues and analogs;

334 Cannabicyclohexanol; and

335 CP 55,940.

336 Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with
337 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
338 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include

339 the following:

340 AM 694;

341 Pravadoline WIN 48,098;

342 RCS 4; and

343 AM 679.

344 [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-
345 naphthalenymethanone. This shall include WIN 55,212-2.

346 Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol
347 structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051,
348 and JWH 133.

349 Adamantoylindoles or any compound containing a 3-(1- Adamantoyl) indole structure with
350 substitution at the nitrogen atom of the indole ring whether or not further substituted in the
351 adamantoyl ring system to any extent. This shall include AM1248.

352 Tetramethylcyclopropylindoles or any compound containing A 3-
353 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring
354 whether or not further substituted in the indole ring to any extent and whether or not substituted in
355 the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.

356 N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.

357 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
358 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
359 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
360 medical research. Since nomenclature of these substances is not internationally standardized,
361 any immediate precursor or immediate derivative of these substances shall be covered.

362 Tryptamines:

363 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT);

364 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

365 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);
366 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
367 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);
368 5-methoxy- α -methyltryptamine (5-MeO-AMT);
369 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);
370 4-hydroxy Diethyltryptamine (4-HO-DET);
371 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT);
372 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);
373 4-hydroxy Diethyltryptamine (4-HO-DET);
374 FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
375 FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
376 5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
377 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
378 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
379 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
380 Methyl-Ethylaminopentiophenone;
381 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
382 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
383 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
384 carboxamide);
385 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
386 methylbutanoat);
387 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
388 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
389 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
390 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);

391 Methyl-Ethylaminopentiophenone;

392 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);

393 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);

394 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-

395 3- carboxamide);

396 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-

397 methylbutanoat);

398 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

399 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-

400 a][1,4]benzodiazepine);

401 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-

402 benzodiazepin-2-one);

403 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-

404 a][1,4]diazepine);

405 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-

406 a][1,4]benzodiazepine);

407 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

408 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-

409 a][1,4]benzodiazepine);

410 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-

411 a][1,4]diazepine);

412 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-

413 one) ;

414 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine); and

415 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-

416 a][1,4]benzodiazepine).

417 (e) Depressants.

418 4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-

419 carboxamide);

420 Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);

421 2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone,

422 monohydrochloride);

423 4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);

424 Mecloqualone;

425 Methaqualone;

426 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

427 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-

428 a][1,4]benzodiazepine);

429 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-

430 benzodiazepin-2-one);

431 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-

432 a][1,4]diazepine);

433 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-

434 a][1,4]benzodiazepine);

435 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

436 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-

437 a][1,4]benzodiazepine);

438 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-

439 a][1,4]diazepine);

440 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-

441 one);

442 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

443 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
444 a][1,4]benzodiazepine);
445 Declazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
446 one); and
447 Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-
448 a][1,4]diazepine);
449 (f) Stimulants.
450 Aminorex; some other names: aminoxyphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-
451 dihydro-5-phenyl-2-oxazolamine;
452 Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone, alpha-
453 aminopropiophenone, 2-aminopropiophenone and norephedrone;
454 Fenethylline;
455 Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
456 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
457 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one; alpha—
458 methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or
459 mephedrone; 3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone;
460 methylcathinone; AL-464; AL-422; AL- 463 and UR1432;
461 (+-) cis-4-methylaminorex; ((+)-cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);
462 N-ethylamphetamine;
463 N,N-dimethylamphetamine; also known as N,N-alpha- trimethyl-benzeneethanamine;
464 N,N-alpha-trimethylphenethylamine;
465 Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
466 salts of isomers;
467 Substituted amphetamines:
468 2-Fluoroamphetamine;

469 3-Fluoroamphetamine;
470 4-Fluoroamphetamine;
471 2-chloroamphetamine;
472 3-chloroamphetamine;
473 4-chloroamphetamine;
474 2-Fluoromethamphetamine;
475 3-Fluoromethamphetamine;
476 4-Fluoromethamphetamine;
477 4-chloromethamphetamine;
478 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
479 Alpha-PHP (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
480 MPHP (1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
481 PV8 (1-Phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
482 4-Chloro-Alpha-PVP (1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
483 N-Ethylhexedrone (2-(Ethylamino)-1-phenylhexan-1-one);
484 Methoxetamine (2-(Ethylamino)-2-(3-methoxyphenyl)-cyclohexanone); and
485 3-Fluorophenmetrazine (2-(3-Fluorophenyl)-3-methylmorpholine);
486 (g) Temporary listing of substances subject to emergency scheduling. Any material,
487 compound, mixture, or preparation which contains any quantity of the following substances:
488 N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts,
489 and salts of isomers;
490 N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
491 isomers, salts, and salts of isomers.
492 N-benzylpiperazine, also known as BZP;
493 Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
494 4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-

495 butyramide);
496 Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
497 Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
498 acetamide);
499 3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-
500 phenylbutyramide);
501 4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
502 yl)butyramide);
503 Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
504 Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
505 carboxamide); and
506 Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).

507 (h) The following controlled substances are included in Schedule I:
508 Synthetic Cathinones or any compound, except bupropion or compounds listed under a
509 different schedule, or compounds used within legitimate and approved medical research,
510 structurally derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic
511 or fused polycyclic ring systems, whether or not the compound is further modified in any of the
512 following ways:

513 By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,
514 hydroxyl, or halide Substituents whether or not further substituted in the ring system by one or
515 more other univalent substituents;
516 By substitution at the 3-position with an acyclic alkyl substituent;
517 By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
518 groups;
519 By inclusion of the 2-amino nitrogen atom in a cyclic structure; or
520 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as

521 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
522 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
523 medical research.

524 (i) Notwithstanding §60A-2-204(d) of this code, if an organic psilocybin substance or drug
525 that contains the pharmaceutical composition of crystalline polymorph psilocybin, known as
526 COMP360 or any such trade name approved by the United States Food and Drug Administration,
527 is approved by the United States Food and Drug Administration and scheduled by the Drug
528 Enforcement Administration, it shall be lawful to prescribe, distribute, and market based upon the
529 recommendations of the United States Food and Drug Administration and the United States Drug
530 Enforcement Administration.

NOTE: The purpose of this bill is to add crystalline polymorph psilocybin in the permitted list of distributed and prescribed drugs, if approved by the United States Food and Drug Administration and scheduled by the United States Drug Enforcement Administration.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.